Literature DB >> 27001939

Expression of death receptor 3 on peripheral blood mononuclear cells differes in adult IBD patients and children with newly diagnosed IBD.

Tomasz J Slebioda1, Agnieszka Bojarska-Junak2, Marta Cyman1, Piotr Landowski3, Barbara Kaminska3, Krzysztof Celinski4, Zbigniew Kmiec1.   

Abstract

BACKGROUND: Interaction between TL1A and death receptor 3 (DR3) is associated with the pathogenesis of inflammatory bowel disease (IBD), although their role in the development of this disease remains not fully explained. Some studies showed elevated expression of TL1A and DR3 in inflamed intestinal tissue but currently there are no reports concerning expression of DR3 on peripheral blood mononuclear cells (PBMCs) of IBD patients which was the subject of our study.
METHODS: We performed flow cytometry analysis of DR3 expression on CD4(+), CD8(+), CD11c(+), CD14(+) or CD20(+) PBMCs of adults and children with IBD and healthy volunteers with respect to C-reactive protein (CRP) levels in blood. Blood samples were collected from pediatric patients before the beginning of therapy, whereas adults patients were undergoing anti-inflammatory IBD treatment and had much lower CRP levels.
RESULTS: With regard to appropriate healthy volunteers, children with IBD had elevated percentage of DR3-expressing CD4(+), CD8(+), CD11c(+) and CD20(+) PBMCs which, with the exception of DR3(+) CD11c(+) cells in children with ulcerative colitis, was correlated with CRP level in blood. Adult patients had increased frequency of DR3(+) CD8(+) and CD20(+) PBMCs and their CRP levels correlated only with DR3(+) CD8(+) cells.
CONCLUSIONS: In comparison to healthy volunteers, untreated children with IBD have higher percentage of DR3(+) PBMCs than adults with IBD undergoing anti-inflammatory treatment. In most of the investigated PBMCs populations, the frequency of DR3(+) cells is correlated with the level of CRP. We suggest anti-inflammatory treatment may lead to reduction in the frequency of DR3(+) PBMCs.
© 2016 International Clinical Cytometry Society. © 2016 International Clinical Cytometry Society.

Entities:  

Keywords:  TL1A; death receptor 3; inflammatory bowel disease; peripheral blood mononuclear cells

Mesh:

Substances:

Year:  2016        PMID: 27001939     DOI: 10.1002/cyto.b.21372

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  4 in total

Review 1.  Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review).

Authors:  Yunhong Yu; Peng Jiang; Pan Sun; Na Su; Fangzhao Lin
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

Review 2.  TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity.

Authors:  Vassilis Valatas; George Kolios; Giorgos Bamias
Journal:  Front Immunol       Date:  2019-03-27       Impact factor: 7.561

3.  Candidate single nucleotide polymorphisms of irritable bowel syndrome: a systemic review and meta-analysis.

Authors:  Shiwei Zhu; Ben Wang; Qiong Jia; Liping Duan
Journal:  BMC Gastroenterol       Date:  2019-10-15       Impact factor: 3.067

4.  Oestrogen-deficiency induces bone loss by modulating CD14+ monocyte and CD4+ T cell DR3 expression and serum TL1A levels.

Authors:  Fraser L Collins; Michael D Stone; Jane Turton; Laura R McCabe; Eddie C Y Wang; Anwen S Williams
Journal:  BMC Musculoskelet Disord       Date:  2019-07-12       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.